8-K: Capricor Reports Q2 Loss, Seeks Deramiocel BLA Resubmission

Capricor Therapeutics announced its second quarter 2025 financial results, reporting increased losses and zero revenue, while actively pursuing resubmission of its Deramiocel BLA following a Complete Response Letter and advancing its exosome platform.

Summary

• Capricor Therapeutics reported a net loss of approximately $25.9 million, or $0.57 per share, for Q2 2025, compared to a net loss of $11.0 million, or $0.35 per share, for Q2 2024.
• Revenues for Q2 2025 were $0, a decrease from approximately $4.0 million in Q2 2024, due to full recognition of prior milestone payments from Nippon Shinyaku by December 31, 2024.
• Total operating expenses increased to approximately $27.7 million in Q2 2025 from $15.6 million in Q2 2024.
• Cash, cash equivalents, and marketable securities totaled approximately $122.8 million as of June 30, 2025, down from $151.5 million as of December 31, 2024.
• The company expects its cash balance to support planned operations into the fourth quarter of 2026.
• A Type A meeting with the U.S. FDA is scheduled for August 2025 to discuss the path forward for Deramiocel's Biologics License Application (BLA) following a Complete Response Letter (CRL).
• Capricor aims to resubmit the BLA based on its existing HOPE-2 and open-label extension data, with HOPE-3 data (expected Q4 2025) potentially serving as supportive evidence.
• All 483 observations noted in the Pre-License Inspection (PLI) have been resolved and accepted by the FDA, indicating readiness for commercial manufacturing.
• The FDA cleared the Investigational New Drug (IND) application for the StealthX exosome-based vaccine, with a Phase 1 clinical trial initiated by NIAID in August 2025.
• Deramiocel received Orphan Drug Designation for Becker muscular dystrophy (BMD).

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. The significant financial losses and zero revenue, coupled with the major setback of a Complete Response Letter (CRL) for their lead product, are strong negatives. However, the proactive steps to address the CRL, successful resolution of manufacturing observations, and the advancement of the promising StealthX exosome platform provide some positive counterbalance and future potential. The cash runway into Q4 2026 is also a positive, but the immediate regulatory hurdle and financial performance weigh heavily.

Positives

• All 483 observations from the Pre-License Inspection (PLI) have been resolved and accepted by the FDA, marking a major milestone for commercial manufacturing readiness.
• The FDA cleared the IND for the StealthX exosome-based vaccine, initiating the first clinical entry for the exosome platform, with a Phase 1 trial started by NIAID in August 2025.
• Four-year results from the HOPE-2 Open-Label Extension (OLE) study showed continued preservation of cardiac function (LVEF) and slowed skeletal muscle decline (PUL v2.0) in Deramiocel-treated patients, with a favorable safety profile.
• Deramiocel was granted Orphan Drug Designation for Becker muscular dystrophy (BMD), expanding its potential market.
• The company's cash balance of approximately $122.8 million is expected to support planned operations into the fourth quarter of 2026, providing a solid financial runway.

Negatives

• Received a Complete Response Letter (CRL) for the Deramiocel Biologics License Application (BLA), indicating that the application is not ready for approval in its current form.
• Reported zero revenue for the second quarter and first half of 2025, a significant decrease from $4.0 million and $8.9 million in the respective prior-year periods.
• Net loss significantly increased to approximately $25.9 million ($0.57 per share) for Q2 2025, compared to $11.0 million ($0.35 per share) for Q2 2024.
• Total operating expenses rose substantially to approximately $27.7 million in Q2 2025 from $15.6 million in Q2 2024, indicating increased burn rate.

Risks

• The ability to obtain regulatory approvals or otherwise bring products to market, particularly for Deramiocel following the CRL.
• The potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval.
• The efficacy, safety, and intended utilization of Capricor's product candidates may not meet expectations.
• The initiation, conduct, size, timing, and results of discovery efforts and clinical trials, including HOPE-3, may not be favorable or timely.
• The pace of enrollment of clinical trials may be slower than anticipated.
• The ability to achieve product milestones and receive milestone payments from commercial partners, such as Nippon Shinyaku, is uncertain.
• Future revenue streams and projections are subject to significant uncertainty, especially given the current lack of revenue.
• The scope, duration, validity, and enforceability of intellectual property rights may be challenged.

Future Outlook

The company anticipates its current cash, cash equivalents, and marketable securities will be sufficient to cover anticipated expenses and capital requirements into the fourth quarter of 2026. This outlook excludes potential additional milestone payments from Nippon Shinyaku and any strategic use of capital not currently planned. The company is actively working with the FDA to define a clear regulatory path for Deramiocel's BLA resubmission, with topline data from the HOPE-3 trial expected in Q4 2025 to potentially serve as supportive evidence. The StealthX exosome platform is expected to advance into therapeutic applications following the initial Phase 1 vaccine trial.

Management Comments

• "We remain steadfast in our mission to deliver the first approved therapy for Duchenne cardiomyopathy—a serious and progressive complication of DMD with no approved treatments."
• "While the receipt of a CRL was a setback, we are working diligently to define a clear regulatory path forward, which has been delineated in our Type A briefing document."
• "Our objective remains to gain approval based on our current Biologics License Application (BLA) submission as expeditiously as possible, with the primary evidence being the totality of data from our HOPE-2 trial and its open-label extension."
• "We are fully prepared to supplement the BLA with HOPE-3 data as needed, with topline results expected in the fourth quarter of 2025. Our upcoming Type A meeting with the FDA will be a critical step in outlining the approval pathway."
• "Importantly, the FDA has now accepted all 483 observations noted in our Pre-License Inspection (PLI), marking a major milestone in our regulatory progress and commercial manufacturing readiness."
• "The FDA’s clearance of the IND for StealthX marks the first clinical entry for our exosome platform and underscores its potential. While this vaccine trial is a meaningful starting point, our broader goal is to advance StealthX into therapeutic applications."
• "Our collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) under Project NextGen reflects our belief in the platform’s potential and may lay the foundation for future strategic partnerships."
• "As we continue to grow this platform, we remain focused on disciplined execution and building long-term value for both patients and shareholders alike."

Industry Context

This announcement reflects the inherent challenges and high stakes in the biotechnology sector, particularly for companies developing therapies for rare diseases like Duchenne Muscular Dystrophy (DMD). The receipt of a Complete Response Letter (CRL) from the FDA is a common hurdle in drug development, underscoring the rigorous regulatory environment. Capricor's proactive engagement with the FDA and resolution of manufacturing observations are standard responses to such setbacks. The expansion into exosome-based therapies with the StealthX platform aligns with a broader industry trend towards novel drug delivery systems and vaccine technologies, often supported by government initiatives like Project NextGen, which seek to accelerate innovation in public health.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders**: Face increased uncertainty regarding the approval timeline for Deramiocel due to the CRL, potentially impacting stock valuation. The increased net loss and zero revenue also indicate a higher burn rate, though the cash runway provides some stability.
• **Patients (DMD/BMD)**: The CRL for Deramiocel means a delay in potential access to a much-needed therapy for Duchenne cardiomyopathy, which has no approved treatments. However, the company's commitment to defining a clear regulatory path offers continued hope.
• **Employees**: The company's continued operations and progress on other programs (StealthX) suggest stability, but regulatory setbacks can create pressure.
• **Regulatory Authorities (FDA)**: The company is actively engaging with the FDA to address the CRL and has successfully resolved PLI observations, demonstrating compliance and commitment to regulatory processes.
• **Commercial Partners (Nippon Shinyaku)**: The delay in Deramiocel approval impacts the timeline for potential commercialization and future milestone payments under the U.S. Distribution Agreement.

Next Steps

• Host a conference call and webcast on August 11, 2025, at 4:30 p.m. ET to discuss financial results and corporate updates.
• Meet with the U.S. FDA in August 2025 for a Type A meeting to discuss next steps following the Deramiocel BLA CRL.
• Seek to resubmit the Deramiocel BLA based on existing data, potentially including HOPE-3 data.
• Await topline data from the HOPE-3 Phase 3 clinical trial, expected in the fourth quarter of 2025.
• Continue the Phase 1 clinical trial for the StealthX exosome-based vaccine, initiated by NIAID in August 2025.
• Participate in several investor conferences in September and October 2025, including Cantor Fitzgerald Global Healthcare, Wells Fargo Healthcare, H.C. Wainwright Annual Global Investment, Cell & Gene Therapy Meeting on the Mesa, Roth Healthcare Opportunities, and Maxim Growth Summit.

Key Dates

Recommendation

The stock is a 'hold' due to a mixed bag of significant challenges and promising developments. The Complete Response Letter (CRL) for Deramiocel's BLA is a major setback, introducing uncertainty and delaying potential revenue. The company's financial performance shows a substantial increase in net loss and zero revenue for the quarter, indicating a high burn rate. However, the company has a clear plan to address the CRL, including an upcoming Type A meeting with the FDA and potential inclusion of HOPE-3 data. Crucially, all manufacturing observations from the Pre-License Inspection have been resolved, which is a positive step towards commercial readiness. Furthermore, the advancement of the StealthX exosome platform into clinical trials represents a new growth avenue. The existing cash runway into Q4 2026 provides financial stability to navigate these challenges. Investors should monitor the outcome of the FDA meeting and HOPE-3 data, as these will be critical catalysts for future valuation.

Keywords

Capricor Therapeutics, CAPR, Duchenne Muscular Dystrophy, DMD, Deramiocel, CAP-1002, Biologics License Application, BLA, Complete Response Letter, CRL, FDA, Exosome, StealthX, Biotechnology, Rare Diseases, Clinical Trials, Financial Results, Orphan Drug Designation, Becker Muscular Dystrophy, BMD, Cardiomyopathy